Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. halorhodopsin -NpHR, respectively), engineered for expression in the mammalian brain, can be genetically targeted into specific neural populations using viral vectors. When exposed to light with appropriate wavelength, action potentials can be triggered in ChR2-expressing neurons, whereas inhibition of action potentials can be obtained in NpHR-expressing neurons, thus allowing for powerful control of neural activity. Optogenetics is now intensively used in laboratory animals, both in vitro and in vivo, for exploring functions of complex neural circuits and information processing in the normal brain and during various neurological conditions. The clinical perspectives of adopting
INTRODUCTION
Neurological diseases can be difficult to treat by traditional pharmacotherapy or surgical interventions, such as deep brain stimulation (DBS). Treatment, cure, and prevention can be obtained in many cases. However, beneficial therapeutic effects achieved by altering brain (mal)functions are often accompanied by harmful and undesired side effects. One major problem is lack of cellular specificity and spatiotemporal targeting exerted by current therapies. More effective approaches that regulate and control specific brain regions and/or specific neural populations when it is required are highly desirable, but are unmet needs of current treatment strategies. With a new bio-genetic technology termed optogenetics (1), highly precise spatiotemporal control of neural activity within defined neural population can be obtained by externally applied light.
Acting like a switch to turn "on" and "off" action potential activity, genetically targeted neurons encoding and expressing microbial light-sensitive transmembrane ion conductive proteins can be controlled in intact neural circuitries ( Figure 1 ). This review article will address recent advances of optogenetics in neuroscience, mainly exemplified by the microbial light-sensitive proteins Chlamydomonas reinhardtii Channelrhodopsin-2 (ChR2) and Natronomonas pharaonis Halorhodopsin (NpHR), and discuss its potential clinical application for several human neurological disorders.
OPTOGENETIC TOOLS
The field of optogenetics has advanced rapidly since 2005 when the technology was first described by a group of scientists from Stanford University headed by Karl Deisseroth (1, 2) . They demonstrated for the first time that neurons expressing the light-sensitive ChR2 protein can generate action potentials in a timely and precise manner when illuminated by light (2).
Channelrhodopsin-2 (ChR2)
Derived from a unicellular alga, ChR2 is a light-sensitive cation channel that is engineered for stable membrane expression and can be introduced into mammalian cells using viral vectors without perturbing the cell integrity (2).
When exposed to ~470 nm blue light, ChR2-expressing neurons are depolarized by a strong and ultrafast current sufficient to induce single or multiple action potentials (Figure 2A, B) . This responsiveness is precise and controllable in a high temporal manner (2) . Further molecular modifications of the gene encoding the ChR2 protein have generated variants with improved functionality, including faster deactivating kinetics and long-lasting activation (3, 4) .
Halorhodopsin (NpHR)
NpHR is a bacteria-derived light-sensitive chloride-pump, and when activated by ~570 nm yellow light, it generates fast chloride ion influx. NpHR has also been genetically engineered for mammalian application and display similar fast temporal control as the ChR2 cation channel. In neurons, activation of NpHR strongly hyperpolarizes the membrane whereby it can effectively suppress action potentials (5, 6) (Figure 2C, D) . Improved NpHR variants that are more well-tolerated and efficient for neural silencing have been created (7, 8) .
Since NpHR and ChR2 proteins are activated by separate wavelengths of light, illumination with proper wavelength allows independent control of ChR2 and NpHR expressing cells for either initiation or inhibition of action potential activity. Ultimately, full bi-directional control of the membrane potential within a single neurons can be obtained, either by co-expression of ChR2 and NpHR (6) or by expression of both proteins together using a single viral vector encoding both opsin genes (termed eNPAC) (7).
Light sources
Light activation of ChR2 and NpHR proteins in neural circuits can be obtained by several means. For in vitro settings, such as brain slices preparation and cultured cells, light sources including xenon arg lamps, LEDs and lasers can provide the proper wavelengths, whereas for in vivo light delivery in living animals, LEDs can be applied for illuminating superficial brain areas (9, 10) . For deeper brain structures, implantable laser-coupled optical fibers are reliable and efficient sources for delivering light into the parenchyma (11, 12) .
Expression systems for controlling neural activity
One major aspect of optogenetics is the delivery of opsin genes into the brain and transduction of neurons. Up to now, direct in vivo gene transfer into the brain by stereotactic injection of viral vectors is the most widely used technique. This approach 6 allows for introducing genes into defined cell types, such as neurons, by using cell population-specific promoters that drive transgene expression. Stable and long-term expression of opsin proteins is also achieved by this approach, and has been proven to be successful in a variety of animal species, including non-human primates (2, 11, (13) (14) (15) (16) .
Lentiviral and adeno-associated viral (AAV) vectors are both suitable mediators for such viral gene transfer (12) . Notably, the AAV viral vector is considered innocuous and nonpathogenic for normal brain physiology, as all viral genes encoding wild type viral proteins are removed to avoid viral replication, toxicity, and reduce immunogenicity (17) . influx into these cells has been shown by using a lentiviral vector carrying the glial fibrillary acidic protein (GFAP) promoter (24), thus demonstrating that expression of opsin proteins can also be successfully obtained in non-neural populations.
Other expression systems are available, but these have generally limited potential in clinical application, and are mostly useful for basic and pre-clinical research. Such approaches include, for example, generation of transgenic mice expressing ChR2 in subset of neurons (15, (25) (26) (27) . Alternatively, using Cre- 
Linking cell activity to animal behavior
Another powerful asset of optogentics is that it can establish a causal link between activity within a specific cell type to behavior in living animals. This is possible by targeting specific neurons for ChR2 expression in combination with light illumination of target areas in freely moving animals. This in vivo approach has, for example, identified that perceptual decisions and learning can be controlled by a subset of excitatory (ChR2-expressing) neurons in the barrel cortex of mice (10) As optogenetics also offers high temporal resolution, patterns of action potentials within single neuron subtypes driving behavioral conditions can also be explored. This is important for expanding our current understanding of causal relationships between frequency-dependent activity within defined cell types and a specific behavior. For example, alteration of dopamine signaling within the VTA is known to be centrally involved in reward behavior (including drug addiction), but how dopaminergic activity contributes to this behavior is unknown. By selectively stimulating ChR2-expressing dopaminergic neurons in VTA of living animals in a conditional place preference paradigm, only high frequency phasic firing (50 Hz), but not low frequency tonic firing (1 Hz), released sufficient dopamine levels to drive behavioral conditioning (30).
Likewise, the role of hypocretin (Hcrt)-expressing neurons in the lateral hypothalamus for participating in the transition from sleep to wakefulness has been elusive. However, by genetic targeting of ChR2 and probing of Hcrt neurons in behaving animals, it was demonstrated that elevation of the action potential frequency in Hcrt neurons led to increased probability of the transition to wakefulness (14, 23) .
AMELIORATION OF NEUROLOGICAL CONDITIONS
It is clear from the studies described above that optogenetics has an enormous potential for exploring the CNS and its functions in previously unprecedented ways. This technique is therefore instrumental for extending our current understanding of normal brain processing, but clearly also opens totally new opportunities for more systematic delineation of disease mechanisms. This may in some cases prove beneficial for better treatments, as described below.
Activation and recovery of breathing
Within the rostral ventrolateral medullary reticular formation, the retrotrapezoid nucleus (RTN) contains propriobulbar neurons, which are suspected to express central respiratory chemoreceptors working as generators for breathing. To selectively address these neurons and delineate their role in respiration, a cluster of non-catecholaminergic glutamatergic neurons expressing paired mesoderm homeobox protein 2B (Phox2b) were targeted in the RTN of rats using a lentiviral vector containing ChR2 (22,43). In two independent studies, light stimulation of the ChR2-transduced neurons via implanted optic fibers vigorously and repeatedly increased both phrenic nerve activation and respiratory activity (22,43), thus providing compelling evidence that these cells play a role in central respiratory chemoreception. Since no other behavioral effects were detected during light stimulation, apart from a small rise in blood pressure (22, 43) , these studies also demonstrate that an optogenetic approach can be used as a strategy to enhance functional respiration. In particular, activation of the phrenic motor nucleus, either directly or via Phox2b expressing neurons in RTN, appears to be an interesting target for enhancing breathing. In line with this notion, repeated optogenetic stimulation of the phrenic motor nucleus (expressing ChR2) significantly improved the respiratory insufficiency observed after partial disruption of descending axons to respiratory motor neurons in the injured spinal cord (44) . Together, these studies demonstrate that novel optogenetic strategies aimed at selectively activating neural populations within the CNS can be a viable approach to enhance breathing and improve respiratory recovery after spinal cord injuries, which lack any other viable therapy at the moment.
Suppression of seizure-like activity
Because NpHR is an effective chloride pump that can significantly hyperpolarize neurons and effectively suppress the generation of action potentials, it could theoretically be used to reduce aberrant hyperexcitation within defined neuronal networks. Gaining such powerful control of neuronal excitability would be of particular interest for controlling seizures in patients with drug resistant focal epilepsies. This concept has been explored in a study using organotypic hippocampal slice cultures, a model tissue system closely resembling pharmacoresistant epileptic brain tissue of both human and animal origin. NpHR was expressed in principal pyramidal and granule cells of the hippocampus, and upon electrical induction of epileptiform activity (i.e. stimulation train induced bursting, STIB), NpHR was simultaneously activated by yellow light illumination of the transduced slice cultures (45) . During such conditions, epileptiform activity could be repeatedly and significantly suppressed, and in some cases even completely abolished (45) (Figure 3A , B, C), thus proving a proof-of-concept for controlling seizure activity by optogenetic silencing of principal neurons.
Amelioration of parkinsonian symptoms
Parkinson's disease is a degenerative neurological disorder characterized by a progressive loss of midbrain domaminergic neurons leading to alteration of neural activity within the basal ganglia causing abnormal control and execution of movements. Besides dopamine agonist administration, DBS of the subthalamic nucleus (STN) in the basal ganglia has emerged as a highly effective method for ameliorating Parkinson's disease symptoms. Exactly how DBS exerts its therapeutic effects is unknown, since electrical stimulation indiscriminately influences a mixed cell population, in which both residing neurons and axons passing or terminating in the STN can be stimulated. However, by using the advantages of optogenetics, systematic delineation of DBS mechanisms have now been addressed in a study of freely moving hemiparkinsonian rodents, wherein amphetamine-induced rotational bias, among others, served as the behavioral test to evaluate the effect of optical stimulation of the STN (24). During light application, it was demonstrated that direct ChR2-mediated enhancement or NpHR-mediated silencing of STN neuron activity was insufficient to induce any symptomatic relief. However, during high frequency light activation of afferent axons projecting to the STN, pronounced therapeutic effects were observed. In this case, parkinsonian animals restored their normal motor behavior, a condition that could be fully reversed when terminating the light stimulation (24). This study is particularly interesting as it clearly demonstrates that by gaining high spatiotemporal control over defined neuronal subtypes in vivo, while leaving other neurons unaltered, it is possible to dissect complicated disease-related mechanisms, gain new knowledge on how therapeutic action is achieved, and also reduce disease symptoms. This is an important step for translating optogenetic strategies into human clinical use.
Recovery of blindness using ChR2 and NpHR
Retinitis pigmentosa (RD) is a genetically inherited disease, characterized by a them. This could be achieved by combining a prosthetic system that delivers preemptive light to the seizure focus triggered by a seizure detection device in a close-loop system (57) . Technical advancements on these matters are needed, but a recent clinical study has shown that optimized patient-specific preonset seizure detection systems can be near 100% correct (58) .
Clinical strategies using optogenetics is probably not limited for CNS diseases. Therapeutic approaches towards disorders affecting the peripheral nervous system are also plausible. Selective optogenetic recruitment of muscle fibers by sciatic nerve activation has been successfully implemented in experimental animals leading to refine physiological muscle contraction without fatigue (59) . In the future, this type of treatment might enable patients with paralysis or motor neuron dysfunction to regain better physiological muscle control.
Concluding remarks
Optogenetics is still a relatively new technology, but has already proven to be a However, as the electrical field also influences other neurons and passing axonal fibers conveying normal physiological activity, side effects can be generated. Illuminating the same slice with yellow light for activating NpHR (yellow bar), while applying an identical electrical stimulation as in A, totally inhibits the generation of epileptiform activity. C) Since NpHR is selectively activated by yellow light, no effect on epileptiform activity is observed during blue light illumination (blue bar). Scale bar applies to all traces. Modified with permission from Proceedings of the National Academy of Sciences, PNAS (45) .
